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introduction: Orchiopexy for congenital cryptorchid testes is recommended between 
½ and 1 year of age to preserve testicular germ cell maturation. Early operation is not 
enough to preserve fertility in 22 and 36% of cases. Aim of this study was to set up a 
protocol for optional adjuvant hormonal therapy after orchiopexy and thereafter cryo-
preservation of testicular biopsies from infants with bilateral cryptorchidism and high 
infertility risk.
Materials and methods: We included 17 boys with bilateral cryptorchidism, normal 
FSH, and impaired germ cell number per tubular transverse section (G/T) in testicular 
biopsies at orchiopexy, 7 months to 3½ years old. Postoperatively, optional adjuvant 
LHRH (kryptocur®) 0.2 mg/0.1 mL 2× every second day in 16 weeks were offered. Ten 
boys were applicable for age matching according to parent’s choice of treatment regime 
and G/T. Five of them had kryptocur®, and five were controls. Repeat bilateral testicular 
biopsy evaluation and cryopreservation were offered to all boys 12 months after primary 
orchiopexy. For cryopreservation, tissue pieces were incubated with a cryoprotectant 
with a slow program freezing.
results: Two out of five kryptorcur®-treated boys normalized both the average G/T and 
the number of adult dark spermatogonia (Ad-S). Another kryptocur®-treated boy with 
initial low G/T and no Ad-S increased the G/T and achieved normal number of Ad-S at 
time of cryopreservation. In the control group, two patients reached only normal lower 
range regarding the G/T and the number of Ad-S. None of boys with less than average 
0.2 G/T improved significantly, whether they were kryptocur®-treated or not.
conclusion: Based on literature and the present results, we recommend adjuvant LHRH 
treatment to boys with cryptorchidism and insufficient genuine gonadotropin stimulation 
at time of surgery, as these patients have high infertility risk. Cryopreservation should 
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be an option in case of treatment failure of adjuvant LHRH. However, to avoid repeat 
surgery with biopsy, some parents may choose biopsy for cryopreservation at time of the 
initial bilateral orchiopexy, well informed that the procedure may only be truly indicated in 
22 and 36% of the cases.
Keywords: cryptorchidism, germ cells, lhrh, cryopreservation of cells and tissues, orchiopexy, fertility
inTrODUcTiOn
Today, orchiopexy for congenital cryptorchid testes is recom-
mended within the first ½–1  year of life to preserve testicular 
germ cell maturation (1–4). In accordance with the strategy of 
early operation follow-up studies on adult men operated for cryp-
torchidism in childhood have shown significant improvement 
of fertility even in bilateral cases (5–7). However, these studies 
have not conclusively proven that early surgery will protect from 
azoospermia development.
For a subgroup of boys with cryptorchidism, early operation 
is not enough to preserve fertility. If, there is an underlying 
endocrinopathy causing inadequate maturation of the testis, 
merely putting the testis into the scrotum may not correct 
that endocrinopathy (4, 8). However, some of the reported 
endocrinopathies may be temporary and part of a maturational 
process. Specifically, there is incomplete evidence whether an 
appropriately time orchiopexy increases adult dark spermatogonia 
(Ad-S) numbers later similar to what LHRH may aid earlier on. 
One author showed that early and successful orchiopexy (before 
9 months of age) could not prevent infertility development in 36% 
of cryptorchid males (1, 7, 9). Cortes et al. (10) found similarly 
that germ cell hypoplasia, which is germ cells per tubular cross 
section value below the lowest normal value for age, was present 
in 22% of the testes in 0- to 1-year-old boys with cryptorchidism. 
From about 15 months of age, germ cells may even start to lack 
and this process will progress (10, 11). Germ cell hypoplasia in 
both testes of prepubertal boys with cryptorchidism at time of 
orchiopexy generally leads to infertility in adulthood (12).
For more than a decade, Hadziselimovic and Hoecht have 
advocated that a group of boys with cryptorchidism and high 
risk of infertility could be identified in infancy according to 
histopathological evaluation of testicular biopsies showing low 
germ cell number and lack of Ad-S in the germinative epithelium 
(1, 2). Recently, Thorup et  al. (13) proposed to combine the 
results of blood samples (gonadotropins and inhibin B) with 
histopathology (bilateral testicular biopsies during orchidopexy) 
to identify the group of patients at high risk of infertility. They 
reported that boys with normal gonadotropin levels and normal 
germ cell number have a good fertility prognosis and boys with 
increased gonadotropin levels may have testicular dysgenesis, 
and some of these boys may benefit from early surgery alone. 
However, boys with normal gonadotropin levels and a decreased 
total number of germ cells and decreased number of Ad-S have 
transient hypothalamus hypofunction and a poor fertility prog-
nosis, as there was no gonadotropin response to the impaired his-
tological state of seminiferous tubules as reflected either directly 
with the mean germ cell count per tubular transverse section 
or indirectly by the serum levels of inhibin B. The reason could 
be a significant prepubertal transient hypothalamus–pituitary–
gonadal hypofunction (14). Impaired transformation of the 
neonatal gonocytes into type Ad-S during the first 12 months of 
age and subsequent apoptosis of germ cells may be a pathogenic 
factor. This transformation may be impaired if gonadotropins 
are insufficient and when the testis is undescended this lead to 
germ cell deterioration. Adjuvant hormonal treatment has been 
used to improve the fertility potential in such cases (15, 16).
For prepubertal infant boys with cryptorchidism, when full 
spermatogenesis is not yet ongoing, cryopreservation of imma-
ture testicular tissue might be an option to try to preserve their 
fertility while germ cells are still present in the cryptorchid testes, 
although the number of germ cells, as previously mentioned, is 
impaired (17, 18). Cryopreservation of testicular tissue has the 
advantage of preservation of integrated tissue. This allows to 
maintain cell-to-cell contact between spermatogonia and the 
neighboring cells, especially Sertoli cells, which are important 
for subsequent maturation of spermatogonia. We and another 
team have reported the freezing protocols of testicular tissue 
in prepubertal boys, both yielding good structural integrity 
(17, 19). Several centers have now established testicular tissue 
banking for prepubertal males at risk of infertility (20, 21). Young 
boys, before starting gonadotoxic cancer treatment (20, 21) or 
undergoing bilateral orchiopexy (21), are offered the option of 
testicular biopsy and cryopreservation under the same general 
anesthesia for either port-a-cath-insertion (for chemotherapy) 
or orchiopexy surgery. A biopsy of about 0.35  mm3, either 5% 
of testicular volume, is considered as a sufficient amount of tis-
sue for culture and transplantation. Although testicular tissue 
preservation offers the prospect of realistic applications, fertility 
restoration after cryopreservation has not yet been successful in 
humans. Nevertheless, promising results of restoration of fertility 
from donor stem cells have been achieved in animals (22).
The aim of this study was to set up and evaluate a useful pro-
tocol for optional adjuvant hormonal therapy and cryopreserva-
tion of testicular biopsies from infant boys with cryptorchidism 
and high risk of infertility. We hypothesize that this strategy is 
relevant, because within a 20-year period the technique of res-




Testicular biopsies at time of orchiopexy were taken and evalu-
ated according to a previous described method (10). All tissue 
specimens were fixed in Stieve’s solution, embedded in paraffin, 
and 2-µm sections were stained with hematoxylin-eosin, CD99 
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(MIC-2) and PLAP. In blinded fashion, the total number of germ 
cells (S/T), including gonocytes and Ad-S, per tubular transverse 
section was measured from at least 100 tubular transverse sec-
tions. For every patient, the mean adult dark spermatogonia per 
tubule (Ad/T) and mean-S/T were found. The mean-S/T was 
considered normal when the value was at least 1.0 at birth, 0.65 
at 6 months and 0.38 in 1- to 4-year-old boys, based on our previ-
ously published normal material (10). The total number of Ad/T 
for each patient was stratified into present (greater than 0.02) or 
abnormal (0.02 or less).
hormonal assays
Blood samples were obtained by venipuncture between 8:00 and 
11:00 a.m. Serum samples were separated from the clot by 10 min 
of centrifugation at 2,000 × g. Serum was stored at −80°C until 
analysis. Serum inhibin B levels were measured using a commer-
cial available inhibin B ELISA kit (Serotec Ltd., Oxford, UK) with 
research kit as recommended by the manufactory instructions. 
The lower detection limit was 5 pg/mL, and the measurements 
were made in duplicate.
LH and FSH were measured by sandwich electrochemilumi-
nescence immunoassay. The lowest value of FSH to be measured 
was 0.05 IU/L. Normal median: 0.5 IU/L and range: 0.1–1.4 IU/L. 
The lowest value of LH to be measured was also 0.05 IU/L. Normal 
median: 0.1 IU/L and range: 0.05–0.3 IU/L.
FSH more than 1.4 IU/L was considered as a high serum value 
for this age group.
Patients and setup
We offered boys age 7  months to 3½  years old with bilateral 
cryptorchidism to join the study if they met the inclusion criteria.
In order for patients to be qualified for inclusion, the average 
germ cell count per tubular transverse section should be between 
0.05 and 0.40. PLAP positive germ cells should be present in the 
biopsy. The serum FSH level should not be increased.
After 3  months postoperatively, when testes should be in 
scrotum and the hormone profile and testicular histology was 
evaluated, the patients were offered adjuvant hormonal treatment 
with LHRH (kryptocur®) 0.2  mg/0.1  mL 2× every second day 
in 16 weeks (dosing according to consensus conference, Cortes 
and Hadziselimovic; Liestal 2009). Patients, with matched germ 
cell number in testicular biopsies, who did not choose hormonal 
treatment were used for controls. Repeat bilateral testicular 
biopsy for histology and cryopreservation were offered to all the 
patients 12 months after the primary orchiopexy.
Cryopreservation was performed according to the following 
protocol: tissue pieces were incubated with a cryoprotectant 
(5% DMSO) with a slow program freezing.
statistics
Non-parametric statistics were used for analyses: Mann–Whitney 
test was used to asses statistical significance, and two-sited 
p values less than 0.05 were considered significant.
Ethics
The study was conducted according to the Helsinki II declara-
tion, and informed consent was obtained from the parents of 
the patients. The study received approval from the ethics com-
mittee of Copenhagen (H-2-2012-060.anm.37655) and Danish 
Medicines Agency (SST jr. nr. LMST-2012083184).
resUlTs
Seventeen boys with bilateral cryptorchidism had testicular 
biopsies taken for cryopreservation. Ten boys were applicable for 
age matching according to parent’s choice of treatment regime 
and histopathological evaluation of germ cell status. These 
boys were included in the study. Five of them had kryptocur®  
treatment and five were controls. None had any associated 
anomalies.
At inclusion, there were no differences between the two groups 
in respect of age (p = 0.92), inhibin-B level (p = 0.69), and the 
average germ cell count per tubular transverse section (p = 0.40) 
(Figure 1).
Two out of five kryptorcur®-treated boys normalized com-
pletely as well the average germ cell count per tubular transverse 
section as the number of Ad-S. One other kryptocur®-treated 
boy with an initial germ cell count per tubular transverse sec-
tion of 0.06 and no Ad-S increased the germ cell count and 
achieved normal number of Ad-S at time of cryopreservation. 
In the control group, two patients reached normal lower range 
regarding the average germ cell count per tubular transverse 
section and the number of Ad-S (Figure  1). None of the 
boys with less than average 0.2 germ cell number per tubular 
transverse section improved significantly, whether they were 
kryptocur® treated or not (Figure  1). There were no surgical 
complications after the re-biopsy procedure. All specimens for 
cryopreservation were prepared, frozen, and stored according 
to the protocol without complications. The median and (range) 
hormonal serum levels at time of orchiopexy and re-biopsy 
for cryopreservation were FSH: 0.7 (0.6–1.4) and 0.4 (0.1–1.7) 
IU/L, respectively; LH: 0.1 (0.05–0.4) and 0.1 (0.05–0.4) IU/L, 
respectively; inhibin B: 114 (17–300) and 55 (28–132 pg/mL), 
respectively.
DiscUssiOn
This is the first study on cryopreservation of testicular tissue 
from infant boys with documented high risk of infertility after 
treatment for cryptorchidism. Although the study sample is 
very modest, we demonstrate important results, which are 
useful for further investigations. Since 2/5 (and one partial) of 
LHRH-treated patients responded, adjuvant LHRH treatment 
to cryptorchid boys with insufficient genuine gonadotropin 
stimulation or in patients with low germ cell count or number 
of Ad-S by testicular biopsy should be instituted at time of 
surgery. However, since 2/5 control patients had almost similar 
improvements in germ cell counts, one could also argue that 
the study does not show any significant difference between 
treated and control patients. Thus, the conclusion should be 
that a larger sample size is needed to fully discern whether 
the germ cell count improvement is truly only seen in LHRH-
treated patients. Our findings are evidently in agreement with 
the research by Hadziselimovic, who states that if germ cell 
FigUre 1 | The average number of germ cells per tubular transverse section from 10 boys with bilateral cryptorchidism at time of orchiopexy and 1 year after, at 
time of cryopreservation. The individual results of primary and follow-up biopsies from five kryptorcur® treated and five bilateral controls without hormonal treatment 
aged 10 months to 3 years are connected with lines [there was no age difference between groups (p = 0.92)].
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count per tubular transverse section is below 0.2, a majority 
of patients will develop infertility irrespective of whether they 
had only surgery or hormonal treatment before orchiopexy 
(9). So, the only realistic way to achieve biological paternity for 
these patients may be through cryopreservation of testicular 
tissue. Great challenges in this respect are obvious. We have 
previously clearly shown that infant testicular biopsies tolerate 
the freezing procedure (19). In that study the morphology of 
the fresh and frozen–thawed samples was similar, with well-
preserved seminiferous tubules and interstitial cells. A similar 
picture appeared after 2 weeks of culture, but a few of the cul-
tured biopsies contained small necrotic areas. The presence of 
spermatogonia was verified by c-kit-positive immunostaining. 
Production of testosterone and inhibin B (ng/mm3 testis tissue) 
in the frozen–thawed pieces were on average similar to that of 
the fresh samples (19). However, although PLAP positive germ 
cells were present in our present selected material, possibly 
representing germ cells with stem cell properties and with pre-
served ability for germ cell transformation (23, 24), presence 
of Ad-S was not identified in all biopsies for cryopreservation. 
Cultivation of a spermatogonia cell population is a prerequisite 
for later restoration of fertility from an autologous donor. So, 
development in our laboratory of a technique for testicular 
autograft enzymatically dispersed leading to single spermato-
gonia stem cell suspension is needed and is now in process.
Although there are too few patients in our study to show 
any statistical significance our data may support the studies in 
a recent review implicating that LHRH treatment increases the 
germ cell number in cryptorchid testes (16): “Hadziselimovic 
and Herzog reported in 1997 that the luteinizing hormone-
releasing hormone analog, Buserelin®, administered intra-
nasally every other day for 6  months following successful 
orchidopexy, appeared to have a long-lasting, positive effect 
on germ cells (15). In another study, Huff et al. (25) reported 
that GnRH treatment after orchidopexy improved total germ 
cell counts in 75% of the patients. These results have partly 
been confirmed by other groups. Schwentner et  al. (26) gave 
intranasal GnRH 1.2  mg/day for 4  weeks preoperatively in 
21 cases versus orchidopexy only in 21 controls. The mean 
number of spermatogonia per tubule was 1.11 in unilateral 
and 0.96 in bilateral cases versus 0.47 and 0.56, respectively, 
in controls. Jallouli et  al. (27) prospectively assigned a total 
FigUre 2 | Histology of testicular biopsies from a boy when he was 1¼ 
and 2¼ years old, respectively. After bilateral orchiopexy for 
cryptorchidism, 4 months of adjuvant LHRH was given. Average germ  
cell number per tubular transverse section increased from 0.27 (a) to 0.55 
(B). Adult dark spermatogonia (Ad-S) are noted in the re-biopsy (B). The 
Ad-S are characterized as large gem cells with pale cytoplasm. In the 
nuclei, a vacuole is observed which appears in the sections as a circular 
light area. Informed consent to show the pictures was given by the 
parents.
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of 24 boys, 12–123  months old (median 34.5), with 24 UDT 
into two groups during a 24-month period. The patients were 
randomized to receive either orchidopexy alone (n =  12) or 
orchidopexy combined with neoadjuvant GnRH therapy 
(kryptocur®) (n = 12) as a nasal spray for 4 weeks at 1.2 mg/day. 
In both groups, testicular biopsies were performed at orchi-
dopexy, and the number of germ cells per tubule was deter-
mined. The mean number of germ cells per tubule in the group 
treated with GnRH before surgery was significantly greater 
(0.88 ±  0.31) than in the group without hormonal stimulation 
(0.49 ±  0.52; p =  0.02). Zivkovic et  al. (28) also found that 
hormonal therapy (Buserelin®) improved the histopathology of 
the abnormal contralateral descended testis in unilateral cryp-
torchidism without harming the germ cells.” Vincel et al. (29) 
presented recently a randomized study of 10 boys 8  months 
to 5 years old. Boys with high infertility risk (no Ad-S in the 
testicular biopsy) were randomly divided into two groups. First 
group underwent just the second orchidopexy without any hor-
monal treatment. The second group received intranasal LHRH 
(Buserelin®) therapy for the period of 6  months followed by 
second orchidopexy. Biopsy was taken from both groups during 
the second surgery. Five boys in each arm were included. There 
was no difference in the mean number of germ cells per tubule 
at the first surgery between the first and the second groups. 
Only the second group showed statistically significant increase 
in the number of germ cells per tubule: medians from 0.11 
to 0.42 (p =  0.04). There were no Ad spermatogonia in both 
groups in the first biopsy. They were detected only in patients 
from the second group, who had adjuvant hormonal therapy, in 
the second biopsy (p = 0.008). These findings are very similar 
to our present results (Figures 1 and 2).
So, adjuvant hormonal therapy stimulating gonadotrophins 
may probably have a positive effect on germ cell maturation 
(16). Due to our previous findings that LHRH in recom-
mended doze may harm the germ cells in young infancy (30), 
we have chosen a lower doze and a longer treatment period in 
the present study. Further pharmaceutical safety studies and 
randomized placebo controlled efficiency studies are needed 
to find the optimal adjuvant treatment regime. However, 
hormonal treatment should be restricted to boys with genuine 
insufficient gonadotropin stimulation, which may also include 
unilateral cryptorchidism with bilateral disease. The hormonal 
changes from orchiopexy to time of re-biopsy are in accord-
ance with the expected changes related physiological decline 
of serum values seen after the minipuberty (31). The weakness 
of the study is related to the modest sample size and the lack 
of a randomized design. Furthermore, there is no guaranty 
that the development of technique for restoration of fertility 
from autologous donor stem cells will be successful within 
15–20  years, although very promising rodent studies have 
recently been published (32).
In 1994, a first report showed that spermatogonia stem cell 
transplantation restored spermatogenesis, resulted in func-
tional sperm and subsequently gave rise to normal offspring in 
mice (33, 34). Till now, spermatogonia stem cell transplanta-
tion has been successful in various species such as pig, bovine, 
and monkey (35–37). In addition, it has been shown that 
spermatogonia stem cells from humans and other species could 
settle in their niche on the basal membrane of testis tubules after 
transplantation into immunodeficient mice but currently there 
is no experience from transplanting spermatogonia stem cells 
to humans (38–41).
cOnclUsiOn
Based on the literature and the present results we recommend 
adjuvant LHRH treatment to boys with cryptorchidism and 
insufficient genuine gonadotropin stimulation at time of surgery, 
as these patients have high risk of infertility. But a larger study 
sample size is needed to fully discern whether the germ cell 
count improvement is truly only seen in LHRH-treated patients. 
Cryopreservation should be an option in case of treatment failure 
of adjuvant LHRH. However, to avoid repeat surgery with biopsy, 
it may be more attractive for some parents to choose biopsy for 
cryopreservation at time of the initial bilateral orchiopexy, well 
informed that the procedure may only be truly indicated in 22 
and 36% of the cases.
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